日辰股份(603755.SH):上半年淨利潤2873.1萬元 同比增長20.68%
格隆匯8月21日丨日辰股份(603755.SH)公佈半年度報吿,報吿期內,公司營業收入和歸屬於上市公司股東的扣除非經常性損益的淨利潤同比均實現雙位數增長。其中:營業收入18,745.09萬元,同比增長15.16%;歸屬於上市公司股東的淨利潤2,873.10萬元,同比增長20.68%;歸屬於上市公司股東的扣除非經常性損益的淨利潤2,742.67萬元,同比增長24.70%。
報吿期內,公司以市場需求為導向,持續加強產品研發力度,不斷豐富產品品類。公司憑藉強大的研發能力實現了以創新驅動的業績成長,報吿期共銷售1,800多款產品,其中近三年開發的新品銷售佔比超過50%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.